☰
×

Clayface: The Body-Horror Film Defying Box Office Odds!

Clayface, the latest body-horror film, is making waves at the North American box office, recently crossing the $50 million mark. Despite facing competition from new releases, it has shown remarkable audience interest and is on track to surpass the earnings of The Suicide Squad. Directed by James Watkins, the film explores the chaotic life of a Hollywood actor turned vengeful entity. As it continues its theatrical run, industry observers are keenly watching its performance against newer films. Will it maintain its momentum and climb higher in the ranks of DC films? Read on to find out more!
 

Clayface's Strong Box Office Performance

The body-horror movie Clayface is showing impressive resilience at the North American box office, steadily making its way up the ranks of DC-related films. Despite facing stiff competition from a slew of new releases, the film has maintained strong audience interest, recently surpassing the $50 million milestone in domestic earnings.

As it enters its third weekend in theaters, Clayface added another $2 million to its total. This figure marks a 38.8% drop from the previous week, which is noteworthy considering it has lost 532 screens from its theatrical release. With a current domestic total of $52 million, the film is on track to exceed the lifetime earnings of James Gunn’s 2021 film, The Suicide Squad.


Box Office Performance and DC Film Rankings

Box Office Trajectory and DC Rankings

According to data from Box Office Mojo, Clayface has already surpassed several other DC films, including Wonder Woman 1984 and Catwoman. With its current earnings, it has secured a spot among the top 40 highest-grossing DC films in the domestic market. It is now less than $5 million away from overtaking The Suicide Squad, which finished its domestic run with $55.6 million.

Directed by James Watkins and released on October 23, the film follows a rising Hollywood star whose life spirals into chaos after transforming into a vengeful figure. The story delves into themes of scientific ambition, identity loss, and the repercussions of obsession. As the film continues its theatrical journey, its ability to sustain momentum against newer releases is a focal point for industry analysts monitoring its final domestic performance.